No statistical differences were obtained when the weight of treatment groups were compared to PLX4032 molecular weight control group or combined therapy was compared to single modality (p > 0.1), suggesting a non-significant minimal overall effect on the mouse weight. A mild increase in weight was observed after axitinib was discontinued in axitinib treated mice and radiation + axitinib treated mice. No obvious signs of toxicity and no skin rashes indicative of bleeding were observed in mice treated with radiation and axitinib, these mice were normally active during the duration of the 3 months experiment. Histological analysis of tissues from kidneys, heart and liver showed no alterations in the vasculature of these organs

by systemic treatment with axitinib alone or combined with radiation, confirming the safety of the drug. Mice were killed if they showed

signs of distress including weight loss, lethargy and tumors in limbs, due to cancer spread. Two control mice with high lung tumor burden developed tumors in limbs and Selleckchem CCI-779 metastatic hilar lymph nodes by day 77. Overall survival in this experiment by day 88 was 50% for control mice, 100% for mice treated with axitinib for 10 weeks, 75% for mice treated with axitinib for 5 weeks, 88% in mice treated with radiation and 100% in mice treated with axitinib and radiation. No statistical differences were obtained in the survival of mice at day 88 in the comparison of single modality treatment groups versus combined modality treatment groups (p = 0.72). The therapeutic effect of axitinib and radiation of mice treated with the schedule described in Table 1A was assessed in

lung tissue sections processed for H&E staining. In the control group, mice surviving up to 70-88 days had very large tumor nodules, which histologically presented as large pleomorphic tumor cells with cytoplasmic vacuoles, large nuclei and prominent nucleoli (Figure 1A), compatible with poorly differentiated adenocarcinoma. Some of the large nodules were hemorrhagic and necrotic (Figure 1B). The number of measurable Roflumilast tumor nodules was estimated at 30-40 per lung, some were not countable as they coalesced replacing large lung areas (Table 2). A wide range of sizes was measured however most of them were very large, and hemorrhagic with a mean area of 110×104 μm2 (Table 2). These tumors showed a high proliferation index by Ki-67 staining with an average of about 110 positive nuclei per nodule (Figure 1C). The lung tissue showed a mix of normal lung alveoli and focal areas of thick alveolar septa with hemorrhages which were observed in the vicinity of tumor nodules (Figure 1B). Following treatment with axitinib, several tumor nodules were still observed in the lung (Figure 1D, Table 2), but these nodules were significantly smaller than in control mice with a mean area of 10×104 μm2 (p = 0.001, Table 2) and contained chronic inflammatory infiltrates (Figure 1D).